Key Takeaway
Retatrutide showed greater weight loss than tirzepatide (Mounjaro) in early clinical trials, with up to 24.2% body weight loss versus 20-22% for tirzepatide. Both drugs are made by Eli Lilly, but retatrutide[2] isn't yet approved.
Retatrutide produced greater weight loss than tirzepatide (Mounjaro/Zepbound) in early clinical trials. Phase 2 data showed up to 24.2% body weight loss with retatrutide over 48 weeks, compared to approximately 20 to 22% with tirzepatide over 72 weeks. Both drugs are manufactured by Eli Lilly, but retatrutide[2] adds a third receptor target and isn't yet FDA approved.
Detailed Explanation
Mounjaro (tirzepatide) is a dual-agonist that targets GLP-1 and GIP receptors. It received FDA approval for type 2 diabetes in 2022 and is also marketed as Zepbound for chronic weight management. Tirzepatide represented a significant advance over single-agonist GLP-1 drugs like semaglutide.
Retatrutide builds on tirzepatide's dual-agonist approach by adding glucagon receptor activation, making it a triple-agonist. The glucagon component is designed to increase energy expenditure, promote fat oxidation, and reduce liver fat. This third mechanism may explain the additional weight loss observed in trials.
Clinical Trial Results Side by Side
In the SURMOUNT-1 trial[1], tirzepatide at its highest dose (15 mg) produced an average weight loss of 22.5% over 72 weeks in adults with obesity. In retatrutide's Phase 2 trial, the highest dose (12 mg) produced 24.2% weight loss in just 48 weeks[2], and the weight loss curve had not plateaued at the end of the study, suggesting even greater losses might occur with longer treatment.
This comparison is notable because retatrutide achieved slightly more weight loss in a considerably shorter time frame. But these were different trials with different patient populations, making a precise comparison imperfect.
Eli Lilly's Product Strategy
Both drugs come from the same manufacturer. If retatrutide is approved, Eli Lilly will likely position it as a next-generation option rather than a direct replacement for tirzepatide. The two drugs may serve different patient segments based on factors like severity of obesity, metabolic comorbidities, tolerability, and cost.
Tirzepatide has the advantage of an established safety record, extensive real-world usage data, and existing insurance coverage pathways. Retatrutide will need to build this track record from scratch after approval.
What to Consider
- Mounjaro is available now. Tirzepatide can be prescribed today by licensed providers, while retatrutide is likely years away from reaching pharmacies.
- Phase 2 results may not fully predict Phase 3 outcomes. Larger trials sometimes produce different efficacy and safety results than smaller Phase 2 studies.
- The glucagon component is a double-edged sword. While it may boost weight loss, glucagon activation can raise blood sugar. This effect needs careful evaluation in patients with type 2 diabetes.
- Side effect profiles appear similar. Both drugs share the gastrointestinal side effects common to incretin-based therapies. Phase 3 data will clarify whether retatrutide's triple mechanism causes additional side effects.
- Individual response varies. Some patients respond better to certain receptor combinations. A physician can help determine which approach is most appropriate for your situation.
Related Questions
Frequently Asked Questions
What weight loss results has retatrutide shown in trials?
Phase 2 trial data published in the New England Journal of Medicine showed participants lost up to 24.2% of body weight at the highest dose over 48 weeks[2]. Phase 3 trials are evaluating these results in larger, more diverse patient populations. Check out our see real Zepbound results for detailed data.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Placebo | 2 | ~2% weight loss |
| 4 mg | 17 | ~17% at 48 weeks |
| 8 mg | 22 | ~22% at 48 weeks |
| 12 mg | 24 | ~24% at 48 weeks |
When will retatrutide be available?
Retatrutide is currently in Phase 3 clinical trials. If trial results are positive, Eli Lilly could submit for FDA approval as early as 2025-2026, with potential commercial availability following approval. Timelines are subject to change based on regulatory review.
How does retatrutide differ from semaglutide and tirzepatide?
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, compared to semaglutide (GLP-1 only) and tirzepatide (GLP-1 and GIP). This triple mechanism showed higher average weight loss in early clinical trials.
Medical References
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [PubMed | ClinicalTrials.gov | DOI]
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. [PubMed | ClinicalTrials.gov | DOI]
Take the Next Step
Mounjaro and other proven GLP-1 treatments are available right now through physician-supervised telehealth. FormBlends provides personalized consultations with licensed providers who can prescribe the best option for your weight loss goals. Start your free consultation today.